• Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab...
    37 KB (3,213 words) - 00:29, 30 September 2024
  • Thumbnail for PD-1 and PD-L1 inhibitors
    CSCC who are not candidates for curative surgery or curative radiation. Dostarlimab (Jemperli) – was developed by GlaxoSmithKline and was first approved...
    35 KB (3,450 words) - 03:38, 30 September 2024
  • Thumbnail for Colorectal cancer
    stage II or III rectal adenocarcinoma were administered single-agent dostarlimab, an anti–PD-1 monoclonal antibody, every three weeks for six months....
    146 KB (15,930 words) - 20:53, 7 November 2024
  • Thumbnail for Pembrolizumab
    inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
    80 KB (7,412 words) - 02:30, 16 October 2024
  • inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
    9 KB (603 words) - 00:28, 30 September 2024
  • Thumbnail for Nivolumab
    inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
    46 KB (4,813 words) - 05:06, 15 October 2024
  • inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
    9 KB (460 words) - 00:28, 30 September 2024
  • for breast and ovarian cancer. TSR-042 TSR-022 Dostarlimab – In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults...
    5 KB (364 words) - 23:58, 12 September 2024
  • inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
    13 KB (1,060 words) - 00:29, 30 September 2024
  • Thumbnail for Endometrial cancer
    hormone replacement therapy after treatment for endometrial cancer. Dostarlimab has been approved by the FDA for therapy of endometrial cancer with specific...
    105 KB (10,821 words) - 12:23, 31 July 2024